Are pigs a suitable animal model for in vivo metabolism studies of new psychoactive substances? A comparison study using different in vitro/in vivo tools and U-47700 as model drug.


Journal

Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027

Informations de publication

Date de publication:
01 Sep 2020
Historique:
received: 16 01 2020
revised: 27 03 2020
accepted: 02 04 2020
pubmed: 8 5 2020
medline: 17 6 2020
entrez: 8 5 2020
Statut: ppublish

Résumé

Being highly potent, New Synthetic Opioids (NSO) have become a public health concern. Little is known though about the metabolism and toxicokinetics (TK) of many of the non fentanyl NSO such as U-47700. Obtaining such data in humans is challenging and so we investigated if pigs were a suitable model species as TK model for U-47700. The metabolic fate of U-47700 was elucidated after intravenous administration to one pig in vivo and results were compared to metabolic patterns formed by different other in vitro systems (human and pig liver microsomes, human liver S9 fraction) and compared to rat and human in vivo data. Furthermore, monooxygenase isozymes responsible for the major metabolic steps were elucidated. In total, 12 phase I and 8 phase II metabolites of U-47700 could be identified. The predominant reactions were N-demethylation, hydroxylation, and combination of them followed by glucuronidation or sulfation. The most predominant monooxygenase catalyzed conversions were N-demethylation, and hydroxylation by CYP3A4 and 2B6, and FMO3 catalyzed N-oxidation. Similar main phase I metabolites were found in vitro as compared to in vivo (pig/human). The metabolic pattern elucidated in the pig was comparable to human in vivo data. Thus, pigs seem to be a suitable animal model for metabolism and further TK of U-47700.

Identifiants

pubmed: 32380122
pii: S0378-4274(20)30109-0
doi: 10.1016/j.toxlet.2020.04.001
pii:
doi:

Substances chimiques

Benzamides 0
Psychotropic Drugs 0
U-47700 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-19

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Frederike Nordmeier (F)

Institute of Legal Medicine, Saarland University, 66421 Homburg, Germany.

Adrian Doerr (A)

Institute of Legal Medicine, Saarland University, 66421 Homburg, Germany.

Matthias W Laschke (MW)

Institute for Clinical and Experimental Surgery, Saarland University, 66421 Homburg, Germany.

Michael D Menger (MD)

Institute for Clinical and Experimental Surgery, Saarland University, 66421 Homburg, Germany.

Peter H Schmidt (PH)

Institute of Legal Medicine, Saarland University, 66421 Homburg, Germany.

Nadine Schaefer (N)

Institute of Legal Medicine, Saarland University, 66421 Homburg, Germany.

Markus R Meyer (MR)

Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, 66421 Homburg, Germany. Electronic address: markus.meyer@uks.eu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH